Dr. Fauci Funded the Sudan Bio Lab Seized by Extremists
By CHARLES DOWNS
Fauci is connected to the Sudanese biolab that’s been seized by extremist fighters in the nation’s ongoing civil war.
On Tuesday, the World Health Organization warned of a “huge biological risk” after rebels took control of Sudan’s National Public Health Laboratory. United States government records show that Dr. Fauci’s NIH significantly funded the National Public Health Laboratory in Sudan.
Records show that Fauci’s National Institute of Health and The Bill and Melinda Gates Foundation provided 20 million dollars in grants to study cholera at the National Public Health Laboratory in Sudan. The study was titled “Dried Blood Spots for Measuring Vibrio Cholera-specific Immune Responses.”
Cholera is one of the diseases the World Health Organization fears could escape from the Sudan bio lab. Cholera causes severe dehydration and can be deadly.
Records also show that the CDC revealed in 2022, “In May 2018, CDC supported the establishment of the first viral load monitoring facility at South Sudan’s National Public Health Laboratory (NPHL),”
Following Tuesday’s horrific news, Dr. Peter A. McCullough, who has stood firm against the MRNA Covid Vax, wrote, “Biological threat research must be halted. Another lab breach on the verge. Fighters occupy bio lab in Sudan holding samples of polio and measles, creating an “extremely, extremely dangerous” situation, @WHO warned Tuesday.”
Laura Loomer pointed out Tuesday night that “Marburg Virus PCR Testing Kits Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits Gee! Just in time for the conflict in Sudan where rebels have just taken control of a bioweapons lab.”
United States and World Health officials have yet to provide a timetable for the all-clear. It has also been reported that the Biden Administration is considering sending troops to Sudan for “evacuation purposes.”
‘Huge biological risk’ after Sudan fighters occupy lab: WHO
Fighters have occupied a national public laboratory in Sudan holding samples of diseases including polio and measles, creating an “extremely, extremely dangerous” situation, the World Health Organization warned Tuesday.
Fighters “kicked out all the technicians from the lab… which is completely under the control of one of the fighting parties as a military base,” said Nima Saeed Abid, the WHO’s representative in Sudan.
He did not say which of the fighting parties had taken over the laboratory.
Abid said he had received a call from the head of the national lab in Khartoum on Monday, a day before a US-brokered 72-hour ceasefire between Sudan’s warring generals officially came into effect after 10 days of urban combat.
“There is a huge biological risk associated with the occupation of the central public health lab,” said Abid.
He pointed out that the lab held so-called isolates, or samples, of a range of deadly diseases, including measles, polio and cholera.
The UN health agency also said there had been 14 attacks on healthcare facilities or personnel during the fighting, leaving eight healthcare workers dead and two injured.
And it warned that “depleting stocks of blood bags risk spoiling due to lack of power.”
“In addition to chemical hazards, bio-risk hazards are also very high due to lack of functioning generators,” Abid said.
The Sudanese health ministry has put the number of deaths so far at 459, with a further 4,072 wounded, the WHO said Tuesday, adding it had not been able to verify that number.
– 270,000 could flee –
The UN refugee agency said thousands had already fled the violence and that it was bracing for up to 270,000 people to flee Sudan into neighbouring Chad and South Sudan.
UNHCR said it does not yet have estimates for the numbers headed to other surrounding countries.
Laura Lo Castro, the agency’s representative in Chad, said some 20,000 refugees had arrived there since the fighting began 10 days ago.
Speaking to reporters in Geneva via video-link, she said the UNHCR expected up to 100,000 “in the worst-case scenario”.
Her colleague in South Sudan, Marie-Helene Verney, said that around 4,000 of the more than 800,000 South Sudanese refugees living in Sudan had returned home since the fighting began.
Looking forward, she told reporters that “the most likely scenario is 125,000 returns of South Sudanese refugees into South Sudan”.
Up to 45,000 Sudanese might also flee as refugees into South Sudan, she said.
– ‘Staring into the abyss’ –
Jens Laerke, spokesman for the UN humanitarian agency, said the fighting had led to “acute shortages of food, water, medicines and fuel, and limited communications and electricity.”
“The people of Sudan, already deeply affected by humanitarian needs, are staring into the abyss.”
Some 15.8 million people in Sudan — a third of the population — already needed humanitarian aid before the latest violence erupted.
But humanitarian operations have also been heavily affected by the fighting, Laerke warned, highlighting among other things reports of looting of humanitarian supplies and warehouses.
Five humanitarian workers have been killed.
Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits
Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.
The Marburg Virus Real Time PCR Kit is an in-vitro diagnostic test, based on real-time PCR technology, for the detection of ribonucleic acid (better known as RNA) from the Marburg Virus. The Company intends to launch the kit into areas accepting a CE mark.
Virax’s Chairman of the Board and Chief Executive Officer, James Foster commented, “We are committed to developing and distributing innovative diagnostic tools to combat infectious diseases. Our Marburg Virus PCR testing kit is a significant step forward in our mission to improve global health.”
The Marburg Virus Disease is a highly virulent disease which causes hemorrhagic fever and requires assessment under the International Health Regulations by the World Health Organization. Given the severity of the disease, the use of accurate and reliable test kits is critical to ensure the best possible outcomes for individuals affected by the disease, as well as for safeguarding public health more broadly.
About Virax Biolabs Group Limited
Founded in 2013, Virax Biolabs Group Limited is an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases.
In addition to distributing an array of in-vitro diagnostic test kits, Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral threats. T-Cell testing can be particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Safe Harbor Statement
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Virax’s Annual Report on Form 20-F for the year ended March 31, 2022. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.